134 related articles for article (PubMed ID: 29641663)
1. The ORBITA trial: A point of view.
Oliveira VD; Giugni FR; Martins EB; Azevedo DFC; Lima EG; Serrano Júnior CV
Rev Assoc Med Bras (1992); 2018 Feb; 64(2):100-103. PubMed ID: 29641663
[TBL] [Abstract][Full Text] [Related]
2. Rethinking revascularization in patients with stable angina.
Harskamp RE; Park DW
Expert Rev Cardiovasc Ther; 2018 Mar; 16(3):159-161. PubMed ID: 29338462
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
[TBL] [Abstract][Full Text] [Related]
4. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
[TBL] [Abstract][Full Text] [Related]
5. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader FA; Chotai S; Pathimagaraj RH; Mohsin M; Salih A; Wang D; Dixit P; Davies JR; Keeble TR; Cosgrove C; Spratt JC; O'Kane PD; De Silva R; Hill JM; Nijjer SS; Sen S; Petraco R; Mikhail GW; Khamis R; Kotecha T; Harrell FE; Kellman P; Francis DP; Howard JP; Cole GD; Shun-Shin MJ; Al-Lamee RK
Lancet; 2024 Apr; 403(10436):1543-1553. PubMed ID: 38604209
[TBL] [Abstract][Full Text] [Related]
6. The argument of the ORBITA study: angioplasty is useless.
Bolognese L
Eur Heart J Suppl; 2020 Jun; 22(Suppl E):E34-E36. PubMed ID: 32523435
[TBL] [Abstract][Full Text] [Related]
7. The ORBITA trial: Why is it not the last nail for coronary angioplasty in stable angina patients?
Rodriguez AE
Cardiovasc Revasc Med; 2019 Jan; 20(1):80-81. PubMed ID: 30056021
[No Abstract] [Full Text] [Related]
8. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
Nowbar AN; Francis DP; Al-Lamee RK
Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
[TBL] [Abstract][Full Text] [Related]
9. In adults with stable angina, PCI vs. a placebo procedure reduced angina symptoms at 12 wk.
Bavishi C
Ann Intern Med; 2024 Mar; 177(3):JC28. PubMed ID: 38437691
[TBL] [Abstract][Full Text] [Related]
10. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials.
Rashid M; Stevens C; Wijeysundera HC; Curzen N; Khoo CW; Mohamed MO; Aktaa S; Wu J; Ludman PF; Mamas MA
J Am Heart Assoc; 2022 Sep; 11(18):e025426. PubMed ID: 36102261
[TBL] [Abstract][Full Text] [Related]
11. Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA.
Bhatt DL; Gersh BJ; Steg PG; Harrington RA; Windecker S
Circulation; 2018 Jun; 137(23):2427-2429. PubMed ID: 29669787
[No Abstract] [Full Text] [Related]
12. The ORBITA trial and the future of percutaneous coronary intervention for stable angina.
Konigstein M; Ben-Yehuda O
Coron Artery Dis; 2018 Sep; 29(6):447-450. PubMed ID: 29664742
[No Abstract] [Full Text] [Related]
13. A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader F; Pathimagaraj RH; Nijjer S; Sen S; Petraco R; Clesham G; Johnson T; Harrell FE; Kellman P; Francis D; Shun-Shin M; Howard J; Cole GD; Al-Lamee R
EuroIntervention; 2024 Feb; 20(3):e216-e223. PubMed ID: 38214677
[TBL] [Abstract][Full Text] [Related]
14. Critical analysis of the classic indications for myocardial revascularization.
Azevedo DFC; Lima EG; Ribeiro MOL; Linhares Filho JPP; Serrano Júnior CV
Rev Assoc Med Bras (1992); 2019 Mar; 65(3):319-325. PubMed ID: 30994826
[TBL] [Abstract][Full Text] [Related]
15. Is Exercise Treadmill Time or Reduction in Myocardial Ischemia the Appropriate Primary Endpoint to Assess Success of Percutaneous Coronary Intervention in Stable Angina (ORBITA)?
Dilsizian V; Erario M
J Nucl Med; 2018 Jan; 59(1):1-2. PubMed ID: 29217737
[No Abstract] [Full Text] [Related]
16. Revascularization with percutaneous coronary intervention does not affect androgen status in males with chronic stable angina pectoris.
Gosai JN; Charalampidis P; Nikolaidou T; Parviz Y; Morris PD; Channer KS; Jones TH; Grech ED
Andrology; 2016 May; 4(3):486-91. PubMed ID: 27027684
[TBL] [Abstract][Full Text] [Related]
17. ORBITA: What Goes Around, Comes Around… Or Does It?
Jackson M; Zaman A
Interv Cardiol; 2018 Sep; 13(3):135-136. PubMed ID: 30443270
[TBL] [Abstract][Full Text] [Related]
18. [Percutaneous coronary intervention vs coronary artery bypass grafting for patients with stable angina pectoris].
Legrand V
Rev Prat; 2015 Mar; 65(3):352-6. PubMed ID: 26016194
[TBL] [Abstract][Full Text] [Related]
19. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease.
Gössl M; Faxon DP; Bell MR; Holmes DR; Gersh BJ
Circ Cardiovasc Interv; 2012 Aug; 5(4):597-604. PubMed ID: 22896575
[No Abstract] [Full Text] [Related]
20. ORBITA Trial: Redefining the Role of Intervention in the Treatment of Stable Coronary Disease?
Albuquerque LC; Gomes WJ
Braz J Cardiovasc Surg; 2018; 33(1):III-V. PubMed ID: 29617511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
